Conference-week snapshot, data through October 1, 2026 · Sep 23–26, 2026 · Glasgow, UK · 852 curated posts · interactive retweet/mention graph. Part of the KOL Pulse IMS26 Conference Intelligence series.
Follow-up: click any KOL card to isolate their retweet graph and see who moves their content; click a state on the map to pull the verified physicians there with institution and trial interests — the people to follow up with after Glasgow, organized the way you plan territory. The trial dropdown filters the graph to the voices already discussing a specific readout.
Reading the network: node size is reach, edges are actual retweets and mentions from the conference window — not follower counts. Clusters show which communities (US academic, EU cooperative groups, patient organizations, media) are organized around which topics.
Amplifiers vs authors: the leaderboard ranks who writes; the amplifier board below ranks who spreads. If you want a message carried into the post-IMS26 conversation, the amplifier list is the distribution map.
Data through October 1, 2026. Engagement (retweet/quote) enrichment is ongoing for this corpus — the network below reflects whatever retweet data has landed so far and will fill in as enrichment continues.






















Create a free account, pick the tumor types you cover, and go beyond the tweet — the intelligence pharma teams use to map influence and prepare for engagement:
| Account | Category | Institution | Location | Topics & Trials | Tweets | Impressions |
|---|---|---|---|---|---|---|
Vincent Rajkumar | US KOL | Mayo Clinic, Rochester | MN | BCMA ADCs (Belantamab)Bispecific T-Cell EngagersCAR-T TherapyCERVINOPERSEUS | 17 | 104.0K |
Rahul Banerjee, MD, FACP | US KOL | Fred Hutchinson Cancer Center / Universi | WA | Bispecific T-Cell EngagersCAR-T TherapyCELMoDs & IMiDsAnito-cel-Phase1CARTITUDE-2 Cohort A | 45 | 75.5K |
Samer Al Hadidi, MD,MS,FACP | US KOL | UT Southwestern Medical Center | TX | Bispecific T-Cell EngagersCAR-T TherapyCELMoDs & IMiDsAnito-cel-Phase1CAMMA 1 | 55 | 37.5K |
Mehak Trehan | Intl KOL | Fortis Memorial Research Institute (FMRI | India | BCMA ADCs (Belantamab)Bispecific T-Cell EngagersCAR-T TherapyProMMiseTRIlogy-1 | 31 | 17.5K |
Mohamad Mohty | Intl KOL | Hôpital Saint-Antoine, Sorbonne Universi | France | Bispecific T-Cell EngagersCAR-T TherapyCELMoDs & IMiDsCERVINODURGA-6 | 9 | 16.4K |
Hamza Hashmi | US KOL | Medical University of South Carolina (MU | SC | BCMA ADCs (Belantamab)Bispecific T-Cell EngagersCAR-T TherapyCAMMA 1CARTITUDE-2 Cohort A | 38 | 14.8K |
Hira Mian | Intl KOL | McMaster University / Juravinski Cancer | Canada | Bispecific T-Cell EngagersCAR-T TherapyMRD & Response DepthCERVINO | 10 | 11.0K |
Joshua Richter, MD, FACP | US KOL | Tisch Cancer Institute, Mount Sinai | NY | Bispecific T-Cell EngagersCAR-T Therapy | 13 | 10.9K |
Al-Ola A Abdallah MD (USMIRC) | US KOL | University of Kansas Medical Center | KS | Bispecific T-Cell EngagersCAR-T TherapyCELMoDs & IMiDsAnito-cel-Phase1CERVINO | 7 | 7.9K |
Henry C Fung | US KOL | Fox Chase Cancer Center | PA | Bispecific T-Cell EngagersCAR-T TherapyCELMoDs & IMiDsCEPHEUSCERVINO | 7 | 7.3K |
Saurabh Zanwar | US KOL | Mayo Clinic, Rochester | MN | Bispecific T-Cell EngagersCAR-T TherapyAnito-cel-Phase1CARTITUDE-4 | 7 | 7.0K |
Ankit kansagra | US KOL | Tampa General Hospital Cancer Institute | FL | Bispecific T-Cell EngagersFrontline NDMM & QuadrupletsMRD & Response DepthCERVINOEXCALIBER-RRMM | 10 | 5.8K |
Rafael Fonseca MD | US KOL | Mayo Clinic, Arizona | AZ | CAR-T TherapyTRIlogy-1 | 3 | 5.7K |
Murali Janakiram | US KOL | City of Hope | CA | Bispecific T-Cell EngagersCAR-T TherapyCELMoDs & IMiDs | 6 | 4.9K |
Yi Lin | US KOL | Mayo Clinic Comprehensive Cancer Center | MN | CAR-T TherapyDART | 7 | 4.2K |
Eddie Cliff | US KOL | Peter MacCallum Cancer Centre / Royal Me | MA | — | 1 | 4.0K |
Breno Moreno de Gusmão | Intl KOL | BP - A Beneficência Portuguesa de São Pa | Brazil | BCMA ADCs (Belantamab)Bispecific T-Cell EngagersCAR-T TherapyCAMMA 1CERVINO | 18 | 3.4K |
Mansi Shah | US KOL | Rutgers Cancer Institute of New Jersey ( | NJ | — | 2 | 2.7K |
Urvi Shah | US KOL | Memorial Sloan Kettering Cancer Center | NY | CAR-T Therapy | 1 | 2.4K |
Rakesh Popat | Intl KOL | UCLH / UCL | UK | Bispecific T-Cell Engagers | 2 | 2.4K |
Gurbakhash Kaur | US KOL | Mount Sinai Health System, NY | NY | BCMA ADCs (Belantamab)CAR-T TherapyFrontline NDMM & Quadruplets | 4 | 2.3K |
Bhausaheb Bagal | Intl KOL | Tata Memorial Center, Mumbai | India | — | 4 | 2.3K |
Meral Beksac | Intl KOL | Liv Hospital / Istinye University | Turkey | Transplant & MaintenanceCARTITUDE-4DURGA-6 | 6 | 2.3K |
Pablo Tenorio Feixas | Intl KOL | King's College Hospital NHS Foundation T | UK | Bispecific T-Cell EngagersCAR-T TherapyDisease Monitoring & Mass SpecCERVINO | 16 | 2.0K |
Eric Smith | US KOL | Dana-Farber Cancer Institute | MA | Bispecific T-Cell Engagers | 1 | 1.7K |
Thanos Dimopoulos | Intl KOL | National and Kapodistrian University of | Greece | EXCALIBER-RRMM | 2 | 1.6K |
Raj Chakraborty | US KOL | Columbia University / Herbert Irving CCC | NY | Bispecific T-Cell Engagers | 1 | 1.4K |
Dr. Minoo Battiwalla | US KOL | Sarah Cannon / TriStar Centennial, Nashv | TN | CAR-T Therapy | 4 | 1.2K |
Shaji Kumar | US KOL | Mayo Clinic Rochester | MN | — | 1 | 1.1K |
Simon Stern | Intl KOL | Epsom and St Helier University Hospitals | UK | Transplant & Maintenance | 2 | 875 |
Want to learn more about your network — your reach, engagement, and influence across IMS 2026 and the wider oncology conversation? Sign up for a free custom KOL report.
A force-directed map of who actually moves the IMS 2026 conversation: 530 accounts connected by 1129 real retweet, quote, and mention relationships from the conference window — not follower counts. 176 of the mapped accounts are verified physicians, spanning 29 countries. The leaderboard ranks the authors; the amplifier board ranks the 501 accounts doing the spreading — led by Rahul Banerjee, MD, FACP with 140 posts amplified.
Take Vincent Rajkumar, the meeting’s most prolific voice: amplified by 211 distinct accounts, 371 times. The makeup of that amplifier network: 92 physicians, 9 patient advocates, 2 media accounts — a clinical audience, not bot inflation. The US physicians who amplify this content most: Rahul Banerjee, MD, FACP (9), Gurbakhash Kaur (6), Mike Thompson, MD, PhD, FASCO (6), Surbhi Sidana, MD (5); internationally, Tontarn Chutima (8), Adrián Alegre, MD, PhD (7). That is the practical answer to “who do they influence?”: the named, verified carriers who move a KOL’s content into each community. Click any KOL card above to run the same analysis visually on their retweeter graph.
Engagement sequencing: the leaderboard tells you who writes, the amplifier board tells you who spreads, and the edges tell you which specific accounts connect them. If a readout needs to reach US academic myeloma during IMS26 week, the amplifier list is the distribution map — and influence-mapping practice guides note that knowing the carriers prevents redundant outreach to already-saturated voices. Pair with the attendee network for rosters by state, institution, and trial interest.
Congress weeks are when oncology opinion forms: standards shift with each readout and physicians learn about the data from each other in real time — surveys report over 70% of HCPs use digital channels weekly, and in a LiveWorld–Sermo survey, 41% of US physicians said social media influences prescribing. Publication records show who built the evidence; this graph shows who carries it — measured in actual retweet relationships, before the meeting begins.
Paste this URL into ChatGPT, Gemini, Claude, or Perplexity and ask the questions this graph answers: “Who are the top amplifiers of IMS 2026 content and what kinds of accounts are they?”, “What is the makeup of Vincent Rajkumar’s amplifier network?”, “Which US physicians amplify the leading international voices?” For who-is-attending questions (states, institutions, trial interests), use the attendee network. Cite kolpulse.com when you share the answers.